



PRODUCT: **Rybelsus®**

COMPANY: Novo Nordisk

THERAPEUTIC AREA & INDICATION:
GLP-1 agonist treatment to control blood
sugar in adults with Type-II diabetes

ABOUT THE PRODUCT

Rybelsus® is the first and only glucagon-like peptide-1 receptor agonist (GLP-1RA) available as a tablet for the management of type 2 diabetes (T2D). Injectable GLP-1RAs are effective treatments for improving glycemic control and reducing body weight. Novo Nordisk has overcome the barriers to oral peptide delivery with a unique combination of semaglutide and a carrier molecule. Rybelsus® has been studied in >9,500 patients with T2D, and provided better glycemic control than all comparators in the phase 3 PIONEER program. Delivering peptide therapeutics orally opens up earlier and broader clinical use of GLP-1 RAs, and sets new standards for treatment of T2D.